Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMVP Health Care Lyme IV Coverage Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Medicare Part B: Lyme Disease/IV Antibiotic Treatment

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage and prior authorization requirements for intravenous antibiotics used to treat Lyme disease, including diagnostic confirmation, qualifying clinical manifestations, oral-therapy limitations, documentation, and treatment-duration requirements.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Lyme Disease/IV Antibiotic Treatment
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for ceftriaxone, cefotaxime, or penicillin G potassium used to treat Lyme disease.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3IV antibiotic codes requiring prior authorization
    14–28 daysRecommended IV treatment duration
    5 of 10Minimum IgG immunoblot bands over 30 days
    2 of 3Minimum IgM immunoblot bands up to 30 days

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >28 daysNot medically necessary treatment duration

    Coverage Criteria

    Covered IV antibiotic therapy

    IV antibiotics for Lyme disease are covered when all of the following criteria are met.

    Required coverage criteria

    • A. Initial serology: Current laboratory results indicate a positive or equivocal enzyme immunoassay, such as ELISA.Positive or equivocal
    • B. Confirmatory serology

      • Confirmatory test pathway

        • Western immunoblot pathway: For symptoms lasting more than 30 days, an IgG immunoblot includes at least five of the specified 10 bands; for symptoms lasting 30 days or less, the qualifying IgG immunoblot must also be accompanied by an IgM immunoblot with at least two of the specified three bands.IgG: ≥5/10 bands; IgM for symptoms ≤30 days: ≥2/3 bands
        • Second enzyme immunoassay pathway: A second enzyme immunoassay is positive.Positive
    • C. Oral therapy limitation or qualifying exception: There is a contraindication or intolerance to all appropriate first-line oral antibiotic therapy at recommended maximum dosages, or the condition is neurologic early Lyme disease or Lyme disease-related parenchymal involvement of the brain or spinal cord.All appropriate first-line oral agents or stated exception
    • D. Qualifying disease manifestation

      • Neurologic early Lyme disease: Meningitis, cranial neuropathy, radiculoneuropathy, or another peripheral nervous system manifestation with clinical and laboratory evidence, such as lymphocytic cerebrospinal fluid pleocytosis or elevated CSF findings.Clinical and laboratory evidence
      • Parenchymal brain or spinal cord involvement: Lyme disease-related parenchymal involvement is evident by MRI imaging or focal neurologic examination findings.MRI or focal examination findings
      • Carditis associated with early Lyme disease is documented, such as atrioventricular heart block or myopericarditis.Documented carditis
      • Lyme arthritis:
    • E. Specialist evaluation: When neurologic or cardiac manifestations are absent, chart notes from appropriate specialists document that underlying conditions with similar symptoms have been ruled out.Specialist evaluation when applicable
    • F. Evidence-based medical necessity: Treatment with IV antibiotics is supported by medical guidelines or peer-reviewed literature and meets MVP clinical coverage criteria for medical necessity.Guideline or peer-reviewed support

    Not medically necessary prolonged or retreatment therapy

    Retreatment and prolonged therapy are not medically necessary under the stated circumstances.

    Not medically necessary treatment patterns: Additional or prolonged antibiotic therapy lacks demonstrated benefit; retreatment is not recommended unless relapse is shown by reliable objective measures, and long-term IV antibiotic therapy exceeding 28 days is not medically necessary.>28 days or retreatment without objective relapse

    Additional or prolonged antibiotic courses are not covered when they have not demonstrated benefit and may expose the individual to significant medication-related adverse effects.

    Treatment is not covered when the indication, age, dose, dosing frequency, or duration falls outside FDA-approved package labeling.

    Intravenous antibiotic therapy exceeding 28 days is not covered as medically necessary.

    Treatment based on a positive ELISA is not covered unless the result is confirmed by a striped-type immunoblot approved by the FDA and currently recommended by the CDC.

    Treatment of post-Lyme disease or post-Lyme disease syndrome is not covered; symptomatic therapy is recommended.

    Additional therapy after the recommended treatment course is not covered for persistent or recurring nonspecific symptoms, including fatigue, pain, or cognitive impairment, when there is no objective evidence of reinfection or treatment failure.

    Prophylaxis for Lyme disease is not covered when the individual has no clinical symptoms.

    IV antibiotic treatment is not covered when provided for nonspecific symptoms alone, such as fatigue or headache.

    Long-term IV antibiotic therapy exceeding 28 days is not medically necessary. Retreatment is not recommended unless relapse is demonstrated by reliable objective measures; prolonged therapy has shown little benefit in prospective, controlled clinical trials.

    Additional treatment for persistent or recurring nonspecific symptoms is not medically necessary without objective evidence of reinfection or treatment failure.

    Coding and Treatment Parameters

    Codes Requiring Prior Authorization when used for the treatment of Lyme DiseaseHCPCSCovered
    J0696Ceftriaxone, per 250 mg
    J0698Cefotaxime, per gram
    J2540Penicillin G potassium, up to 600,000 units
    Recommended IV antibiotic treatment duration
    Recommended duration14–28 days
    TreatmentIntravenous antibiotic therapy
    Applicable diseaseLate-stage Lyme disease or disseminated disease with neurologic or cardiac involvement
    IgG immunoblot for symptoms lasting more than 30 days
    Symptom durationMore than 30 days
    TestIgG Western immunoblot
    Required resultAt least 5 of 10 specified bands present

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for intravenous antibiotics used to treat Lyme disease under the Medicare Part B medical benefit.

    • J0696 — ceftriaxone, per 250 mg
    • J0698 — cefotaxime, per gram
    • J2540 — penicillin G potassium, up to 600,000 units
    Step Therapy

    Oral Antibiotic Therapy Prerequisite

    Document a contraindication or intolerance to all appropriate first-line oral antibiotic therapy at the recommended maximum dosages before requesting intravenous therapy, except for specified neurologic indications.

    • Exception: neurologic early Lyme disease
    • Exception: Lyme-disease-related parenchymal involvement of the brain or spinal cord
    • Reference applicable 2020 IDSA/AAN/ACR Lyme disease guidelines

    Clinical Background

    Lyme disease is a multisystem infection caused by the tick-borne spirochete Borrelia burgdorferi. It may present as early localized, disseminated, or late-stage disease. Oral antibiotics are generally standard therapy for early localized or early disseminated disease without neurologic or cardiac involvement, while IV antibiotics may be indicated for late-stage disease or disseminated disease with neurologic or cardiac involvement. Recommended IV treatment duration is generally 14 to 28 days.

    Definitions and Testing

    Early localized Lyme disease
    StageEarly localized Lyme disease
    Characteristic findingGenerally characterized by a bull's-eye rash
    Rash locationAt the site of the tick bite
    Disseminated Lyme disease
    StageDisseminated Lyme disease
    Typical timingDuring the first few weeks to 6 months after infection
    Disease courseA stage of Lyme disease occurring after early localized disease and before late-stage disease
    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Lyme Disease/IV Antibiotic Treatment
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for ceftriaxone, cefotaxime, or penicillin G potassium used to treat Lyme disease.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Treatment ParametersPrior Authorization and DocumentationClinical BackgroundDefinitions and Testing
    Persistent joint swelling is present with no or minimal response to an initial course of oral antibiotic treatment, with serum antibody testing or, for seropositive members, PCR applied to synovial fluid or tissue.
    Persistent swelling and inadequate oral response
  1. Late neurologic disease affects the central or peripheral nervous system.CNS or peripheral nervous system involvement

    Retreatment is not recommended unless relapse is shown by reliable objective measures.

  2. IgM immunoblot for symptoms lasting 30 days or less
    Symptom duration30 days or less
    TestIgM Western immunoblot, in addition to the qualifying IgG immunoblot
    Required resultAt least 2 of 3 specified bands present
    Maximum IV antibiotic treatment duration
    Maximum duration28 days
    Therapy exceeding the maximumIntravenous antibiotic therapy in excess of 28 days is not medically necessary
    RetreatmentNot recommended unless relapse is shown by reliable objective measures
    Documentation Required

    Document Oral-Therapy Limitation

    Submit documentation showing a contraindication or intolerance to appropriate first-line oral antibiotics, unless an exception applies. The medical record should identify the oral therapies considered and the reason they cannot be used.

    • Document the relevant contraindication or intolerance for each appropriate first-line oral option
    • Include recommended maximum dosages when describing prior oral therapy
    • Exceptions may apply for neurologic early Lyme disease or parenchymal brain or spinal cord involvement

    Unsupported block type: documentation

    Documentation Required

    Document Immunoblot Band Results

    Document immunoblot results according to symptom duration. The required IgG and IgM band thresholds must be shown in the submitted laboratory report.

    • Signs or symptoms >30 days: IgG immunoblot with at least 5 of 10 specified bands
    • Signs or symptoms ≤30 days: meet the IgG requirement and show at least 2 specified IgM bands
    • IgG bands include 18, 21 (OspC), 28, 30, 39 (BmpA), 41 (Fla), 45, 58 (not GroEL), 66, and 93 kDa
    • IgM bands include 24 (OspC), 39 (BmpA), and 41 (Fla) kDa
    Documentation Required

    Qualifying Clinical Manifestation

    Document early disseminated or late Lyme disease with a qualifying clinical manifestation supporting intravenous treatment.

    • Neurologic early Lyme disease, including meningitis, cranial neuropathy, radiculoneuropathy, or other peripheral nervous system manifestations with clinical and laboratory evidence
    • Parenchymal brain or spinal cord involvement supported by MRI or focal neurologic findings
    • Carditis, such as atrioventricular heart block or myopericarditis
    • Lyme arthritis or late neurologic disease affecting the central or peripheral nervous system
    Documentation Required

    Lyme Arthritis Evidence

    For Lyme arthritis, document persistent joint swelling with no or minimal response to an initial course of oral antibiotic treatment and provide supporting serologic evidence.

    • Document serum antibody testing
    • For seropositive members, PCR may be applied to synovial fluid or tissue
    Documentation Required

    Specialist Evaluation Required

    Submit chart notes from an appropriate specialist when neurologic or cardiac manifestations are absent. The notes must show that underlying conditions with similar symptoms have been considered and ruled out.

    • Relevant specialists may include a rheumatologist, cardiologist, or neurologist
    • Include the differential evaluation and rationale for excluding alternative diagnoses
    Documentation Required

    Evidence-Based Medical Necessity

    The request must demonstrate that intravenous antibiotic treatment is supported by medical guidelines or peer-reviewed literature and meets MVP Clinical Coverage Criteria for medical necessity.

    • Include guideline or peer-reviewed literature support when relevant
    • Explain how the requested treatment meets MVP medical-necessity criteria
    Denial Risk

    Excluded or Prolonged Treatment

    Additional or prolonged intravenous antibiotic treatment is not considered medically necessary when it exceeds 28 days or falls outside FDA-approved package labeling.

    • Intravenous antibiotic therapy in excess of 28 days is excluded
    • Treatment outside FDA-approved indication, age, dose, dosing frequency, or duration is excluded
    • Retreatment is not recommended unless relapse is shown by reliable objective measures
    Denial Risk

    Incomplete Documentation Creates Denial Risk

    Requests may be denied when required medical-necessity documentation is incomplete, including testing, qualifying manifestations, oral-therapy limitations, specialist evaluation, or treatment rationale.

    • Missing current ELISA or equivalent enzyme immunoassay and confirmatory testing
    • Missing immunoblot band results or qualifying clinical manifestation
    • Missing documentation of contraindication or intolerance to appropriate first-line oral therapy
    • Missing specialist notes or guideline and peer-reviewed literature support
    Late-stage Lyme disease
    DefinitionUntreated Lyme disease that has progressed for more than 6 months
    DurationMore than 6 months
    Possible manifestationsEncephalitis, encephalomyelitis, arthritis, neuropathies, and cerebral arteritis
    Two-step Lyme disease testing
    First stepEnzyme immunoassay, such as ELISA
    Follow-up triggerA positive or indeterminate first-step result
    Second stepWestern immunoblot or a second FDA-cleared enzyme immunoassay
    Positive testingResults are considered positive only if both the ELISA and the Western immunoblot or second enzyme immunoassay are positive